LIP
NRIX icon

Lighthouse Investment Partners’s Nurix Therapeutics NRIX Stock Holding History

Lighthouse Investment Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$462K – 995
2025
Q3 		$462K Buy
+50,000
New +$519K 0.01% 525

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lighthouse Investment Partners's NRIX Position: Q4 2025 in Review

Lighthouse Investment Partners sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 50,000 shares — an estimated $462K sold.

Lighthouse Investment Partners first reported a position in NRIX in Q3 2025 and held it in 1 quarter. The position peaked at $462K in Q3 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Lighthouse Investment Partners reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lighthouse Investment Partners sold 50,000 Nurix Therapeutics shares in Q4 2025, an estimated $462K.
  • Lighthouse Investment Partners first reported a position in Nurix Therapeutics in Q3 2025 and held it in 1 quarter.
  • Lighthouse Investment Partners's Nurix Therapeutics position peaked at $462K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Lighthouse Investment Partners's 13F filing for Q4 2025, filed 17 Feb 2026.